

ORIGINAL ARTICLE

Incidence and Pathogen Distribution of Healthcare-Associated Infections in Pilot Hospitals in Egypt

Isaac See, MD;^{1,2} Fernanda C. Lessa, MD;¹ Omar Abo ElAta, MD, MPH;³ Soad Hafez, PhD, MS, MBBCh;⁴ Karim Samy, RPh, BPS;³ Amani El-Kholy, MD, PhD;⁵ Mervat Gaber El Anani, MD, PhD;⁵ Ghada Ismail, MD, PhD;⁶ Amr Kandeel, MD, MPH, PhD;⁷ Ramy Galal, MD, MPH;⁷ Katherine Ellingson, PhD;¹ Maha Talaat, MD, MPH, DrPH³

OBJECTIVE. To report type and rates of healthcare-associated infections (HAIs) as well as pathogen distribution and antimicrobial resistance patterns from a pilot HAI surveillance system in Egypt.

METHODS. Prospective surveillance was conducted from April 2011 through March 2012 in 46 intensive care units (ICUs) in Egypt. Definitions were adapted from the Centers for Disease Control and Prevention's National Healthcare Safety Network. Trained healthcare workers identified HAIs and recorded data on clinical symptoms and up to 4 pathogens. A convenience sample of clinical isolates was tested for antimicrobial resistance at a central reference laboratory. Multidrug resistance was defined by international consensus criteria.

RESULTS. ICUs from 11 hospitals collected 90,515 patient-days of surveillance data. Of 472 HAIs identified, 47% were pneumonia, 22% were bloodstream infections, and 15% were urinary tract infections; case fatality among HAI case patients was 43%. The highest rate of device-associated infections was reported for ventilator-associated pneumonia (pooled mean rate, 7.47 cases per 1,000 ventilator-days). The most common pathogens reported were *Acinetobacter* species (21.8%) and *Klebsiella* species (18.4%). All *Acinetobacter* isolates tested (31/31) were multidrug resistant, and 71% (17/24) of *Klebsiella pneumoniae* isolates were extended-spectrum β -lactamase producers.

CONCLUSIONS. Infection control priorities in Egypt should include preventing pneumonia and preventing infections due to antimicrobial-resistant pathogens.

Infect Control Hosp Epidemiol 2013;34(12):1281-1288

Healthcare-associated infections (HAIs) are a significant global threat to patient safety. In the United States, on the basis of data from 2002, HAIs were estimated to cause 99,000 deaths annually, with an incidence in intensive care units (ICUs) of 13.6 HAIs per 1,000 patient-days.¹ Since then, substantial progress has been made toward prevention of HAIs in the United States.^{2,3} However, in the developing world, a recent meta-analysis of HAI data reported a pooled incidence of 46.9 HAIs per 1,000 patient-days, more than a 3-fold greater incidence compared with historical data from the United States.⁴

To identify HAI prevention targets and thus reduce disparities between countries, ongoing surveillance is necessary.⁵ However, resources are severely limited in the developing world, creating difficulties implementing surveillance and establishing effective measures for infection control and HAI prevention.^{6,7} In Egypt, efforts to improve infection control

training and begin HAI surveillance have been under way.⁸ However, previous reports of HAIs in Egypt were limited to device-associated infections and did not address the broad spectrum of HAIs.⁹⁻¹²

In April 2011, in collaboration with the Ministry of Health and Population and university hospitals, the US Naval Medical Research Unit No. 3 (NAMRU-3) implemented a pilot HAI surveillance system in selected hospitals in Egypt to establish baseline HAI rates for a broad spectrum of HAI types. The objectives of the pilot were to determine HAI burden and increase awareness, to inform specific prevention efforts to reduce HAI rates, and to inform planning for a large-scale national surveillance system for HAIs in Egypt. We report the distribution of types and rates of HAI as well as associated pathogen distributions and patterns of antimicrobial resistance.

Affiliations: 1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; 2. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia; 3. Infection Control Unit, Global Disease Detection and Response Program, US Naval Medical Research Unit No. 3, Cairo, Egypt; 4. Department of Infection Control, Alexandria University Hospitals, Alexandria, Egypt; 5. Infection Control Unit, Clinical Pathology and Pediatric Departments, Faculty of Medicine, Cairo University, Cairo, Egypt; 6. Department of Clinical Pathology, Ain Shams University Hospitals, Cairo, Egypt; 7. Ministry of Health and Population, Cairo, Egypt.

Received May 29, 2013; accepted August 18, 2013; electronically published October 30, 2013.

This article is in the public domain, and no copyright is claimed. 0899-823X/2013/3412-0007. DOI: 10.1086/673985

TABLE 1. Description of Types and Number of Intensive Care Units (ICUs), ICU Beds, Patient-Days, and Healthcare-Associated Infections (HAIs) Reported for Each Type of ICU and Pooled Mean HAI Incidence for Each ICU Type

Type of ICU	Units participating	Total beds	Total patient-days	HAIs reported	Pooled mean incidence of HAI, cases per 1,000 patient-days
Adult medical	13	126	23,198	60	2.6
Adult medical/surgical	3	25	2,204	15	6.8
Adult surgical	5	45	6,594	16	2.4
Adult/pediatric medical	1	5	1,471	2	1.4
Adult/pediatric medical/surgical	3	41	11,111	143	12.9
Adult/pediatric surgical	7	42	7,705	76	9.9
Burn	1	14	654	10	15.3
Neonatal ICU	8	113	28,310	105	3.7
Pediatric medical	4	26	7,043	26	3.7
Pediatric surgical	1	30	2,225	19	8.5
Total	46	459	90,515	472	5.2

METHODS

Setting

Prospective surveillance for HAIs was performed in 46 ICUs in 11 Egyptian hospitals from April 2011 through March 2012. Hospitals represented both university-affiliated hospitals and public Ministry of Health and Population hospitals located in Cairo, Giza, Alexandria, Luxor, and Sharm el-Sheikh. All participating hospitals were required to have at least 1 full-time infection control professional, a clinical microbiology laboratory with the capacity to process cultures, at least 1 ICU, and a data manager.

Training and Technical Support

Hospital staff participating in HAI surveillance (eg, physicians, nurses, clinical microbiologists, infection control professionals, laboratory technicians) received a 4-day training course by NAMRU-3 staff that covered topics such as HAI case definitions and diagnosis, test ordering practices for microbiology cultures, microbiology laboratory procedures, and instructions for surveillance data collection and reporting. In addition, NAMRU-3 staff regularly visited participating hospitals to provide continued technical assistance for surveillance.

Definitions

An HAI was considered to be an infection developing during a hospitalization. Major and specific HAI site definitions were adapted from the Centers for Disease Control and Prevention's (CDC's) 2008 National Healthcare Safety Network (NHSN) case definitions.¹³ Because of limitations in laboratory infrastructure, clinical sepsis (which is not currently included in the NHSN) was included among HAIs under surveillance in neonatal ICUs (NICUs). Surgical site infections were not monitored because surveillance focused on infections detected in ICU patients. An infection episode met

HAI criteria when it occurred on or after the third calendar day in the ICU or within 2 calendar days of discharge from the ICU. Serologic and antigen test results were not included in case definitions because laboratories in participating hospitals did not have the capability to perform these tests. In addition, institution of antimicrobial treatment by a physician was not considered sufficient for diagnosis of an HAI because of widespread use of empiric antimicrobial therapy. An infection was defined as device associated (ie, urinary catheter, ventilator, or central line associated) if the corresponding device was in place on the date of infection or within 2 calendar days prior.

ICU type was classified according to NHSN criteria: if 80% or more of the patients were of a given type, then the ICU was classified accordingly (eg, if 90% of an ICU's patients are neonates, then the ICU would be classified as an NICU).¹⁴ In instances where the ICU population consisted of an equal mix of adult and pediatric patients and therefore could not be assigned an existing NHSN location code, new codes for combined adult/pediatric ICUs were created (see Table 1).

Multidrug resistance was defined in accordance with current published interim standard definitions, which were used in the most recent NHSN antimicrobial resistance report.^{15,16} Specifically, an isolate of *Acinetobacter* species was defined as having multidrug resistance if it tested nonsusceptible (ie, resistant or intermediate) to at least 1 drug in 3 of the following 6 antimicrobial agents/groups: piperacillin or piperacillin-tazobactam, extended-spectrum cephalosporins (cefepime or ceftazidime), aminoglycosides, ampicillin-sulbactam, carbapenems, and fluoroquinolones. For *Pseudomonas aeruginosa* isolates, multidrug resistance was defined as testing nonsusceptible (ie, either resistant or intermediate) to at least 1 drug in 3 of the 5 following antimicrobial groups: piperacillin or piperacillin-tazobactam, extended-spectrum cephalosporins (cefepime or ceftazidime), fluoroquinolones, aminoglycosides, and carbapenems.




FIGURE 1. Distribution of healthcare-associated infection types reported, Egypt, 2011–2012 ($n = 472$). Other infection types include bone and joint infection; central nervous system infection; cardiovascular system infection; eye, ear, nose, throat, and mouth infection; and reproductive system infection. BSI, bloodstream infection; GI, gastrointestinal tract infection; LRTI, lower respiratory tract infection; PNEU, pneumonia; SST, skin and soft-tissue infection; UTI, urinary tract infection.

Data Collection

Healthcare workers in ICUs screened patients for signs and symptoms of HAI during clinical rounds 3 days per week as well as by reviewing laboratory and radiology data. Personal digital assistants (PDAs) were used by healthcare workers as decision support devices to perform HAI surveillance. If an HAI was suspected, then information entered into the PDA about the patient's clinical signs and symptoms, microbiology results, and laboratory and radiology testing was run against an HAI case determination algorithm stored in the PDA to evaluate whether case criteria for an NHSN-defined HAI were met. PDA data were uploaded to NAMRU-3 weekly for review and analysis.

Up to 4 pathogens per HAI were recorded. Coagulase-negative *Staphylococcus* species and *Corynebacterium* species were considered pathogens only when isolated from sterile sites. For bloodstream infections (BSIs) specifically, "common commensal" organisms (eg, coagulase-negative staphylococci and *Bacillus* species) were considered pathogens only if isolated from at least 2 blood cultures with signs or symptoms of a BSI, in accordance with NHSN criteria.¹³

Denominator data (ie, patient-days, central line-days, urinary catheter-days, and ventilator-days) were recorded daily by hospital staff on a denominator reporting form, which was sent to NAMRU-3 for electronic data entry.

Data Validation

A team of CDC and NAMRU-3 staff reviewed medical records from 3 ICUs: 1 unit reporting a high HAI rate, and 2 units reporting low rates. Medical records of all patients with a reported HAI and a random sample of controls (ie, patients without an HAI reported) who were present in the selected ICUs during August 2011 were reviewed, for a total of up to 11 patients per ICU. On the basis of available clinical data, the reviewing team determined whether a patient met HAI case definitions. These decisions were considered to be the gold standard for comparison with reported HAI data.

Sensitivity was calculated as $(\text{no. of patients reported to have HAI}) / [(\text{no. of patients reported to have HAI}) + (\text{estimated no. of controls with HAI})]$. The estimated number of controls with HAI was calculated as $[(\text{no. of controls determined to have HAI}) / (\text{no. of controls reviewed})] \times (\text{no. of all controls})$.

TABLE 2. Demographic Characteristics and Clinical Outcomes of Cases of Healthcare-Associated Infections (HAIs) Reported, Egypt, 2011–2012

Variable	All HAIs (n = 472)	PNEU (n = 225)	BSIs (n = 103)	UTIs (n = 69)
Male sex ^a	269 (57)	130 (58)	55 (53)	40 (58)
Age range ^b				
<1 years	132 (28)	44 (20)	71 (69)	2 (3)
1–4 years	26 (6)	11 (5)	4 (4)	2 (3)
5–17 years	45 (10)	29 (13)	5 (5)	6 (9)
18–44 years	100 (21)	47 (21)	10 (10)	27 (39)
45–64 years	103 (22)	52 (23)	7 (7)	24 (35)
≥65 years	62 (13)	41 (18)	3 (3)	8 (12)
Outcome				
Died	203 (43)	95 (42)	40 (39)	32 (46)
Death within 7 days	95 (20)	38 (17)	20 (19)	20 (29)
Discharged	91 (19)	29 (13)	37 (36)	11 (16)
Transfer to another hospital	13 (3)	8 (4)	4 (4)	1 (1)
Transfer within hospital	70 (15)	37 (16)	7 (7)	12 (18)
Unknown	95 (20)	56 (25)	15 (15)	13 (19)

NOTE. Data are no. (%). Numbers for pneumonia (PNEU), bloodstream infection (BSI), and urinary tract infection (UTI) do not sum to total because of HAIs of other types.

^a Sex not reported for 7 cases.

^b Age not known for 4 cases (1 case of PNEU, 3 cases of BSI).

Laboratory Testing

A convenience sample of isolates from HAI cases was sent to NAMRU-3 for verification of identification and antimicrobial resistance testing. All *Klebsiella* species and *Escherichia coli* isolates received by NAMRU-3 were tested for extended-spectrum β -lactamase (ESBL) production by combination disk testing according to guidelines from the Clinical and Laboratory Standards Institute. Inhibition of growth with ceftazidime and cefotaxime disks was compared with ceftazidime-clavulanate and cefotaxime-clavulanate disks, respectively. Isolates were considered to be ESBL producing if the combination disk increased the zone of inhibition by more than 5 mm.

Data Analysis

Patient-days and device-days were pooled by ICU type and hospital. Device utilization ratios (DURs) were calculated as device-days divided by patient-days. Rates for device-associated infections were reported as the number of device-associated infections per 1,000 device-days. Infection rates for other HAIs were reported as the number of infections per 1,000 patient-days. Data analysis was performed using SAS, version 9.2 (SAS Institute).

Human Subjects

The project was approved by the NAMRU-3 Institutional Review Board as a nonresearch protocol (1114).

RESULTS

Characteristics of Participants

From April 2011 through March 2012, 46 ICUs in 11 hospitals (64% general, 18% pediatric, and 18% women's hospitals) reported HAI surveillance data over 90,515 patient-days (Table 1). A median of 3 ICUs from each hospital participated in HAI surveillance (range, 1–11).

Epidemiologic Characteristics and Outcomes of HAI Cases

During the surveillance period, 472 HAIs were reported, with an overall pooled mean incidence of 5.2 HAIs per 1,000 patient-days. The pooled mean incidence of HAI varied by ICU type, from 1.4 HAIs per 1,000 patient-days in adult/pediatric medical ICUs to 15.3 HAIs per 1,000 patient-days in burn ICUs (Table 1).

Pneumonia, primary BSIs, and urinary tract infections (UTIs) together accounted for 84% of all HAIs reported. Most pneumonia and UTI cases were device associated. A minority of BSIs (42%) were central line associated (Figure 1). Among BSIs, 71 (69%) of 103 occurred in patients less than 1 year old, of which 59 (83%) of 71 were laboratory-confirmed BSI and the remainder (12 [17%] of 71) clinical sepsis. Of the HAI case patients identified, 43% died before discharge. In-hospital deaths within 7 days of infection onset, suggesting association between the infection and outcome, occurred in 20% of HAI case patients (Table 2).

TABLE 3. Pooled Mean Device Utilization Ratios (DURs) and Device-Associated Infection (DAI) Rates across All Participating Intensive Care Units (ICUs), Egypt, 2011–2012

DAI type	Device-days	Pooled mean DUR	Percentiles for DUR			DAI cases reported	DAI rate	
			25%	50%	75%		Cases per 1,000 patient-days	Cases per 1,000 device-days
VAP	24,638	0.27	0.09	0.24	0.36	184	2.03	7.47
CLABSI	34,442	0.39	0.17	0.43	0.67	43	0.48	1.25
CAUTI	37,969	0.42	0.19	0.61	0.88	66	0.73	1.74

NOTE. Total patient-days = 90,515. DUR = device-days/patient-days. DURs and DAI rates were calculated by pooling data across all participating ICUs. CAUTI, catheter-associated urinary tract infection; CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia.

Device-Associated Infections

DURs for ventilators, urinary catheters, and central lines and corresponding device-associated infection rates in participating ICUs are summarized in Table 3. The highest device utilization was reported for urinary catheters (median DUR, 0.606). The highest pooled mean rate for device-associated infections was reported for ventilator-associated pneumonia (VAP; 7.5 cases per 1,000 ventilator-days).

Rates of device-associated infections pooled by ICU type are shown in Table 4. The highest central line-associated BSI (CLABSI) rates were reported in NICUs (5.1 cases per 1,000 central line-days).

Data Validation

A total of 26 medical charts were reviewed for data validation, 5 from patients reported to have HAI and an additional 21 from controls. Among patients reported to have HAI, 5 (100%) of 5 were determined to have HAI on external chart review, and 2 (10%) of 21 controls were also found to meet case definitions for HAI. The sensitivity of the system was estimated to be 41%.

Organisms Causing HAI

Among all 472 HAIs, 523 organisms were identified (Table 5). Considering all HAI types together, *Acinetobacter* species

were most commonly reported, accounting for 22% of all organisms, followed by *Klebsiella* species (18% of organisms) and *P. aeruginosa* (16% of organisms); these were the same organisms reported most commonly for pneumonia cases. For BSI, *Klebsiella* species were most commonly reported (26% of organisms), followed by *Staphylococcus aureus* and coagulase-negative staphylococci (14.6% of organisms each). In contrast, for UTI, *Candida* species were most commonly reported (47.6% of organisms), followed by *P. aeruginosa* (13.4% of organisms).

Antimicrobial Resistance

By June 2012, 168 clinical isolates from HAI cases had been processed for identification and antimicrobial susceptibility testing by NAMRU-3 (Table 6). All *Acinetobacter* isolates tested were multidrug resistant, and 84% were carbapenem resistant. In addition, 70% of *E. coli* and 71% of *Klebsiella pneumoniae* isolates tested were ESBL producing. Methicillin resistance was found in 93% of *S. aureus* isolates tested.

DISCUSSION

HAI surveillance data are crucial for informing priorities for infection control. The surveillance data described in this report identify several priority areas for prevention. First, pneumonia, primary BSIs, and UTIs represented more than 80%

TABLE 4. Device-Associated Infection Rates by Intensive Care Unit (ICU) Type, Egypt, 2011–2012

ICU type	ICUs	Central		Ventilator-days	VAP rate	Urinary	
		line-days	CLABSI rate			catheter-days	CAUTI rate
Adult medical	13	7,500	0.93	3,488	4.0	11,635	0.9
Adult medical/surgical	3	1,320	1.52	649	9.2	1,748	1.1
Adult surgical	5	3,456	0.29	1,109	9.0	5,398	0
Adult/pediatric medical/surgical	3	6,813	0.73	5,767	14.2	9,007	3.6
Adult/pediatric surgical	7	5,541	0.54	2,804	10.3	5,739	2.3
Neonatal ICU	8	3,515	5.12	6,097	3.3
Pediatric medical	4	2,946	2.38	2,984	2.0	1,343	0

NOTE. Rates are calculated as healthcare-associated infections per 1,000 device-days. ICU types are included only if more than 500 device-days were reported and more than 1 ICU of the given type reported data (3 ICU types did not meet these criteria and were excluded). Urinary catheter-days and catheter-associated urinary tract infection (CAUTI) rate are not applicable for neonatal ICU. CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia.

TABLE 5. Pathogens Reported during Surveillance for Healthcare-Associated Infections (HAIs), Egypt, 2011–2012

Organism	All HAIs (n = 523)	PNEU (n = 295)	BSIs (n = 96)	UTIs (n = 82)
<i>Acinetobacter</i> species	21.8 (1)	30.2 (1)	12.5 (4)	6.1 (4)
<i>Klebsiella</i> species	18.4 (2)	18.3 (2)	26.0 (1)	7.3 (3)
<i>Pseudomonas aeruginosa</i>	15.7 (3)	17.6 (3)	8.3 (5)	13.4 (2)
<i>Staphylococcus aureus</i>	12.4 (4)	14.9 (4)	14.6 (2)	2.4 (8)
<i>Candida</i> species	9.4 (5)	0 (NA)	8.3 (5)	47.6 (1)
<i>Escherichia coli</i>	5.4 (6)	5.8 (5)	0 (NA)	6.1 (4)
<i>Enterobacter</i> species	3.3 (7)	2.7 (7)	4.2 (7)	3.7 (7)
Coagulase-negative staphylococcus	3.1 (8)	0 (NA)	14.6 (2)	1.2 (9)
<i>Proteus</i> species	2.5 (9)	3.7 (6)	0 (NA)	1.2 (9)
<i>Enterococcus</i> species	2.3 (10)	1.0 (9)	4.2 (7)	6.1 (4)
Other ^a	5.9	5.8	7.3	4.9

NOTE. Data are % of organisms reported (rank order). n = 523 organisms were reported from 350 of 472 HAIs. At least 1 organism was reported for 350 of 472 HAIs, including 168 of 225 pneumonia (PNEU) cases, 83 of 103 bloodstream infections (BSIs), and 66 of 82 urinary tract infections (UTIs). Numbers for PNEU, BSI, and UTI do not sum to total because of HAIs of other types. NA, not applicable.

^a Includes 11 different organisms.

of HAIs reported and should be the focus for infection prevention (eg, prevention of device-associated infections^{17–20}) and continued surveillance efforts. The highest CLABSI rate was reported from NICUs, indicating an important target for CLABSI prevention. Second, gram-negative organisms were commonly associated with HAIs, and high rates of antimicrobial resistance were present in participating ICUs.

This report presents the first surveillance data across all HAI types from Egypt. Surveillance for surgical site infections was not performed in this pilot assessment; otherwise, the distribution of HAI types reported was similar to that reported from recent HAI prevalence surveys from the United States and Argentina.^{21,22} The primary difference is that gastrointestinal infection (mostly caused by *Clostridium difficile*) is one of the main HAI types reported in the United States. In contrast, gastrointestinal infection and *C. difficile* do not appear to contribute substantially to the burden of HAIs in participating ICUs in Egypt.

Pneumonia was the most commonly identified HAI in this pilot surveillance system. However, in Argentina only 45% of pneumonia cases reported were ventilator associated, whereas in the Egyptian ICUs most (85%) cases of pneumonia were ventilator associated. Therefore, not only must proper attention be paid to prevention measures for healthcare-associated pneumonia in general,¹⁹ but specifically practices regarding the care and reprocessing of ventilator equipment should be evaluated closely in the context of VAP prevention measures.²⁰

Comparing rates of device-associated infections between the Egyptian pilot system and the US-based NHSN provides further support for making prevention of VAP a major priority. Rates of CAUTI and CLABSI reported from Egypt (1.7 and 1.2 per 1,000 device-days, respectively) are comparable to NHSN rates reported for many ICU types. However, even

though Egyptian ICUs reported less ventilator utilization than is reported in the NHSN, the VAP rate of 7.5 per 1,000 ventilator-days from Egypt is markedly higher than the pooled mean rates reported from different ICU types in the NHSN (range, 1.1–1.8 among medical ICUs and 2.5–3.5 among surgical ICUs).²³

BSIs were most commonly reported from NICUs; of these BSIs, the majority (83%) were laboratory confirmed, indicating that the high incidence of BSI in NICUs was not an artifact of the inclusion of the clinical sepsis definition. In the United States, a high BSI rate in NICUs has been attributed in part to high utilization of invasive central lines, the duration the lines are in place, and the immaturity of the neonatal immune system.²⁴ Further exploration is needed in the Egyptian hospitals to characterize BSIs occurring in the neonatal population and determine what preventive measures might reduce the burden of nosocomial BSIs in NICUs.

Acinetobacter species and *P. aeruginosa*, 2 of the 3 most commonly reported organisms associated with HAI in Egypt, are notably gram-negative organisms that can persist in the patient care environment. In contrast, *S. aureus* is the most commonly reported pathogen in the NHSN, and *Acinetobacter baumannii* ranks only fourteenth among pathogens reported.¹⁶ The predominance of organisms that may be commonly found in the patient care environment suggests that greater efforts at environmental infection control might play a critical role in reducing or preventing HAI transmission in Egypt.

Furthermore, high-level antimicrobial resistance was reported for an alarming proportion of isolates sent to NAMRU-3. These high rates of resistance are similar to those reported previously for device-associated infections in Cairo University Hospitals,⁹ with approximately 70% of *E. coli* and *K. pneumoniae* isolates tested being ESBL producers. In con-

TABLE 6. Antimicrobial Resistance Patterns for Clinical Isolates of Healthcare-Associated Infection (HAI) Cases Received by the US Naval Medical Research Unit No. 3, Selected Pathogens, 2011–2012

Pathogen, resistance class	Isolates received	Isolates resistant, no. (%)
<i>Staphylococcus aureus</i>	27	
Methicillin resistance		25 (93)
<i>Escherichia coli</i>	10	
ESBL production		7 (70)
Carbapenem resistance		0 (0)
<i>Klebsiella pneumoniae</i>	24	
ESBL production		17 (71)
Carbapenem resistance		5 (21)
<i>Acinetobacter</i> species	31	
Multidrug resistance		31 (100)
Carbapenem resistance		26 (84)
<i>Pseudomonas aeruginosa</i>	23	
Multidrug resistance		13 (57)

NOTE. In total, 168 were isolates processed. Multidrug resistance was defined for *Acinetobacter* species and *P. aeruginosa* as described in "Methods." ESBL, extended-spectrum β -lactamase.

trast, in the United States only approximately 20% of *E. coli* and *K. pneumoniae* isolates reported to the NHSN have extended-spectrum cephalosporin resistance. Resistance rates for other organisms are also substantially higher in Egypt. For instance, 100% of *Acinetobacter* isolates from HAIs in Egypt are multidrug resistant, versus approximately 70% in the NHSN; 93% of *S. aureus* isolates tested in Egypt were methicillin resistant, compared with approximately 50% in the NHSN.¹⁶

Overall, high case-fatality rates were reported in association with HAI. Surprisingly, the highest case-fatality rate among HAI types was reported for UTIs. The reason for this finding is not known. However, one possible explanation is that there might be a bias in Egyptian ICUs toward late clinical diagnosis of UTIs; hence, UTIs might be diagnosed either in patients with more severe underlying illness or late during the course of infection with a more severe clinical course for the infection. In addition, baseline mortality rates for ICU patients are not available to use to determine the mortality attributable to HAI. However, the large proportion of deaths within 7 days of diagnosis suggest that HAIs could play an important role in excess mortality.

In summary, these surveillance data suggest that enhanced hospital environmental infection control, investigating the cause of BSIs in NICUs, evaluation and improvement of ventilator equipment processing, stopping transmission of multidrug-resistant organisms, and carefully evaluating antimicrobial use are critical needs in Egyptian hospitals.

HAI surveillance in the developing world is challenging because of limitations in both experience and resources. Two characteristics of the surveillance system used in this pilot project may have facilitated HAI case finding, data collection,

and reporting. The PDAs programmed with HAI definitions helped surveillance staff apply definitions despite the complexity of the large number of HAI types under surveillance. In addition, most staff performing surveillance focused on data collection in only 1 or 2 ICUs. Given that staff time is scarce in the developing world, distributing the workload of surveillance among healthcare workers might ease the burden on individual staff.

This analysis is subject to the following limitations. First, the hospitals and ICUs participating might not be representative of Egypt. For example, the hospitals enrolled in this pilot were required to meet minimum standards for surveillance (eg, presence of a full-time infection control practitioner and a data manager); thus, resources for case finding, data collection, and reporting in participating hospitals may surpass those available in nonparticipating hospitals. Second, only a limited number of isolates were available for antimicrobial susceptibility testing. As noted, however, results from antimicrobial resistance are similar to other reports from Egypt. Third, these results likely underestimate the true HAI burden. Data validation efforts suggested a low sensitivity for detection of HAI, which likely stems from several factors: (1) case definitions are complex and healthcare workers were unfamiliar with definitions prior to the start of surveillance; (2) owing to limitations in resources, occasionally microbiology and laboratory testing becomes temporarily unavailable; and (3) in Egypt there is widespread use of empiric antimicrobial therapy and limited use of the clinical microbiology laboratory for therapeutic decision making, compared with that in the United States. Indeed, the second and third factors might contribute to why pneumonia, which can be identified without positive culture results, was reported more often than either UTIs or BSIs, which do require laboratory confirmation. Nevertheless, during data validation all reported HAI cases were found to satisfy surveillance criteria for HAI.

Resource limitations create challenges with HAI surveillance in Egypt. To adapt surveillance to these realities, one option would be to modify surveillance definitions to include more syndromic detection of HAIs (ie, fewer requirements for laboratory testing). However, given the high rates of antimicrobial-resistant pathogens isolated, increased awareness that microbiology data are necessary to guide clinician decisions is critical. Moreover, even if more syndromic definitions were implemented, further development in hospital infrastructure might still be needed to allow expansion of HAI surveillance to other hospitals.

This pilot surveillance system demonstrates that despite the challenges experienced during the pilot, implementing HAI surveillance in Egypt is feasible and can identify priorities for intervention. This system represents an important step toward ensuring the safety of patients in Egyptian hospitals. Continuing HAI surveillance can only improve awareness of the need for control of HAIs in Egypt and spur efforts toward global HAI elimination.

ACKNOWLEDGMENTS

We thank the following people for their invaluable assistance coordinating the implementation of the pilot surveillance system: Elham Feky, Hanan El Sayed, and Mona Mohiedden (Cairo University Hospitals); Magda Hanafi (Ain Shams University Hospitals); Elham Hassan, Eman Ahmed, Manal Elnawasany, and Ayad El Sayed (Alexandria University Hospitals); and Sally Mohamed, Mohamed Hamdy, and Magdy Abdu (Ministry of Health and Population).

Financial support. This work was supported by the US Agency for International Development (work unit 263-P-00-10-00005-00). We thank Drs Randy Kolstadt and Akmal El-Erian for their support during the conduct of this work.

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here.

Address correspondence to Isaac See, MD, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop A-24, Atlanta, GA 30333 (isee@cdc.gov).

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the Department of Health and Human Services, the Department of the Navy, or the Department of Defense.

REFERENCES

- Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep* 2007;122:160–166.
- Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant *Staphylococcus aureus* central line-associated bloodstream infections in US intensive care units, 1997–2007. *JAMA* 2009;301:727–736.
- Burton DC, Edwards JR, Srinivasan A, Fridkin SK, Gould CV. Trends in catheter-associated urinary tract infections in adult intensive care units—United States, 1990–2007. *Infect Control Hosp Epidemiol* 2011;32:748–756.
- Allegranzi B, Nejad SB, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *Lancet* 2011;377:228–241.
- Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. *Am J Epidemiol* 1985;121:182–205.
- Tambyah P. Doing good and doing it well, especially where it is not easy. *Infect Control Hosp Epidemiol* 2010;31:142–143.
- Lynch P, Pittet D, Borg MA, Mehtar S. Infection control in countries with limited resources. *J Hosp Infect* 2007;65:148–150.
- Talaat M, Kandeel A, Rasslan O, et al. Evolution of infection control in Egypt: achievements and challenges. *Am J Infect Control* 2006;34:193–200.
- El-Kholy A, Saied T, Gaber M, et al. Device-associated nosocomial infection rates in intensive care units at Cairo University hospitals—first step towards initiating surveillance programs in a resource-limited country. *Am J Infect Control* 2012;40:e216–e220.
- El-Nawawy AA, Abd El-Fattah MM, El-Raouf Metwally HA, El Din Barakat SS, Hassan IA. One year study of bacterial and fungal nosocomial infections among patients in pediatric intensive unit (PICU) in Alexandria. *J Trop Pediatr* 2005;52:185–191.
- Ahmed SH, Daef EA, Badary MS, Mahmoud MA, Abd-Elseyed AA. Nosocomial blood stream infection in intensive care units at Assiut University Hospitals (Upper Egypt) with special reference to extended spectrum β -lactamase producing organisms. *BMC Res Notes* 2009;2:76.
- Saied T, Elkholy A, Hafez SF, et al. Antimicrobial resistance in pathogens causing nosocomial bloodstream infections in university hospitals in Egypt. *Am J Infect Control* 2011;39:e61–e65.
- National Healthcare Safety Network Patient Safety Component Manual. 17. *Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting*. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Accessed November 16, 2012.
- National Healthcare Safety Network Patient Safety Component Manual. 15. *CDC Location Labels and Location Descriptions*. http://www.cdc.gov/nhsn/PDFs/pscManual/15LocationsDescriptions_current.pdf. Accessed November 16, 2012.
- Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268–281.
- Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with health-care-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infect Control Hosp Epidemiol* 2013;34:1–14.
- O’Grady NP, Alexander M, Burns LA, et al. *Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011*. <http://www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html>. Accessed July 29, 2013.
- Healthcare Infection Control Practices Advisory Committee. *Guideline for Prevention of Catheter-Associated Urinary Tract Infections, 2009*. http://www.cdc.gov/hicpac/cauti/002_cauti_toc.html. Accessed July 29, 2013.
- Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003. *MMWR Recomm Rep* 2004;53(RR-3):1–36.
- Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. *Infect Control Hosp Epidemiol* 2008;29(suppl 1):S31–S40.
- Magill SS, McAllister LM, Allen-Bridson K, et al. Preliminary results of a health-care-associated infection and antimicrobial use prevalence survey in 22 U.S. acute care hospitals. In: *Program and Abstracts of the 2011 SHEA Annual Scientific Meeting*. April 1–4, 2011; Dallas. Abstract LB10.
- Durlach R, McIlvenny G, Newcombe RG, et al. Prevalence survey of health-care-associated infections in Argentina: comparison with England, Wales, Northern Ireland and South Africa. *J Hosp Infect* 2012;80:217–223.
- Dudek MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Pollock DA. *National Healthcare Safety Network (NHSN) Report, Data Summary for 2010, Device-Associated Module*. Centers for Disease Control and Prevention. http://www.cdc.gov/nhsn/PDFs/dataStat/NHSN-Report_2010-Data-Summary.pdf. Accessed November 16, 2012.
- Baltimore RS. Neonatal nosocomial infections. *Semin Perinatol* 1998;22:25–32.